Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients

American Journal of Hematology

Volumn 87, Issue 12, 2012, Pages 1047-1051

  Scappini, Barbara ^a   Gianfaldoni, Giacomo ^a   Caracciolo, Francesco ^b   Mannelli, Francesco ^a   Biagiotti, Caterina ^a   Romani, Claudio ^c   Pogliani, Enrico M ^d   Simonetti, Federico ^e   Borin, Lorenza ^d   Fanci, Rosa ^a   Cutini, Ilaria ^a   Longo, Giovanni ^a   Susini, Maria Chiara ^a   Angelucci, Emanuele ^c   Bosi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Division of Hematology Pisa   (Italy)

^c Hematology and Transplant Center Armando Businco Cancer Center   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e Versilia Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; FEMALE; FUNGEMIA; HUMAN; LEUKEMIA REMISSION; LIVER DYSFUNCTION; LUNG ASPERGILLOSIS; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NAUSEA AND VOMITING; NEUTROPHIL COUNT; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SEPTIC SHOCK; SIDE EFFECT;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869192249     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23308     Document Type: Article

References (25)

1. Schiffer CA. Acute myeloid leukemia in adults: Where do we go from here? Cancer Chemother Pharmacol 2001; 48(suppl): S45-S52.
2. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, et al. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J Med Chem 1992; 35: 397-401.
3. Parker WB, Allan PW, Hassan AE, Secrist JAIII, et al. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003; 10: 23-29.
4. Carson DA, Wasson DB, Esparza LM, Carrera CJ, et al. Oral antilymphocyte activity and induction of apoptosis bu 2-chloro-2′.arabino-fluoro-2′deoxyadenosine. Proc Natl Acad Sci USA 1992; 89: 2970-2974.
5. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167-1173.
6. Kantarjian HM, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379-2386.
7. Jeha S, Gaynon P, Razzouk B, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917-1923.
8. Cooper T, Ayres M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005; 55: 361-368.
9. Gandhi V, Kantarjan H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003; 9: 6335-6342.
10. Foran J, Faderl S, Wetzler M, et al. A phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia. Proc Am Soc Clin Oncol 2003; 22:587 (abstract 2360).
11. Faderl S, Gandhi V, O'Brien S, et al. Results of phase 1-2 study of clofarabine in combination with cytarabine (Ara-C) in relapsed and refractory leukemias. Blood 2005; 105: 940-947.
12. Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008; 113: 2090-2096.
13. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 45-51.
14. Litzow MR. The therapy of relapsed acute leukemia in adults. Blood Rev 2004; 18: 39-63.
15. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 93: 2322-2333.
16. Slovak ML, Kopechy KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and posteremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
17. Chevallier P, Labopin M, Turlure P, et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukemia patients: A GOELAMS study. Leukemia 2011; 25; 939-944.
18. Santos FP, Jones D, Qiao W, et al. Prognostic value of FLT3 mutations among different cytogenetics subgroups in acute myeloid leukemia. Cancer 2010; 117: 2145-2155.
19. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
20. Rowe JM, Li X, Cassileth PA, et al. Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative oncology Group Experience. Blood 2005; 106: 162a (abstract 546).
21. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive J Clin Oncol 2010; 28: 2389-2395.
22. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 1638-1645.
23. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 26: 549-555.
24. Gianfaldoni G, Mannelli F, Ponziani V, et al. Early reduction of WT1 transcripts during induction chemotherapy predicts longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010; 9: 833-836.
25. Karp J, Ricklis R, Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 1762-1769.